OPK stands alone as shorts build into earnings week

OPKO Health is the most heavily shorted name among its closest peers by a wide margin. Its short interest reached 5.0% of free float as of 20 October. The next most comparable name in its peer group carries a fraction of that positioning.

Peers moving up, shorts moving in

OPK rose 25.8% over the past week. Its closest peers gained a median of 1.2% over the same period. That gap did not deter short sellers. Short interest climbed 10.9% week-on-week to 38.6 million shares. The weekly build is 3.1 standard deviations above OPK's own typical weekly move over the past year. Short interest is now at its highest level in at least a year.

The borrow market is not signalling stress. Availability sits at 335%, meaning roughly three shares remain available to borrow for every one already lent out. Cost to borrow is 0.50% annually, the lowest in a month. Short sellers are adding positions at elevated cost in stock terms, but at near-zero cost in borrow terms.

What changed since yesterday

The two previous ORTEX convergence reports on OPK, published 19 and 20 October, covered the Barrington Research upgrade to Outperform and the Piper Sandler price target raise to $4.00. Those analyst moves remain in place. The consensus stays at buy, with a mean target of $4.15 against a close of $1.66. What has changed is the stock continued to add ground, and short interest edged slightly lower on the day (down 0.8% on 20 October) after the weekly spike, suggesting the build may be stabilising rather than accelerating.

The put-call ratio on 20 October stood at 0.0363, 1.7 standard deviations below its 20-day mean. That is a shift from 16 October, when it hit 0.0523 and spiked 3.4 standard deviations above the mean. Call positioning has reasserted itself as the dominant options stance over the past two sessions.

Earnings in seven days

OPK reports on 28 October. Two prior earnings prints are in the data: a 10.1% one-day move in July 2026 and a 35.2% one-day move also recorded in late July. Both were to the upside. The bear case rests on a Q1 miss on both revenue and EPS, limited financial flexibility with cash roughly matching debt, and execution risk on the 2H acceleration needed to hit full-year guidance of $530 million to $560 million.

The one number that would materially shift the short picture: a meaningful drop in short interest before the 28 October print would signal conviction fading on the bearish side. For now, 38.6 million shares remain short, availability is ample, and the borrow cost gives bears no reason to cover on cost grounds alone.

---

Data summary

• SI % of free float: 5.0% (20 Oct), highest in at least a year
• Weekly SI change: +10.9%, 3.1 standard deviations above typical weekly move
• Shares short: 38.6 million
• Availability: 335% (ample)
• Cost to borrow: 0.50% annually
• Put-call ratio: 0.0363 (20 Oct), 1.7 std devs below 20-day mean
• Consensus: buy, mean price target $4.15
• Next earnings: 28 October 2026